Switching cannabinoid response from CB2 agonists to FAAH inhibitors

Switching cannabinoid response from CB2 agonists to FAAH inhibitors 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis Conformational Restriction Leading to a Selective CB₂ Cannabinoid Receptor Agonist Orally Active Against Colitis Benzo[d]thiazol-2(3H)-ones as new potent selective CB2 agonists with anti-inflammatory properties 4-Oxo-1,4-dihydropyridines as Selective CB₂ Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB₂Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: Discovery of CB2 receptor selective compounds Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB₂Cannabinoid Receptors Agonists:  Synthesis, Pharmacological Properties and Molecular Modeling